ATS Medical, Inc. has announced it has received U.S. Food and Drug Administration (FDA) approval for the ATS 3f(R) Aortic Bioprosthesis. This is the Company’s first entry into the $400-plus Million U.S. tissue valve market. Based on the precept that ‘Form Follows Function’, the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other replacement valve. The product is based on a proprietary valve design that reproduces the functional characteristics of the native aortic valve.

Researchers from the Stanford University School of Medicine have reported that fenoldopam mesylate, a selective dopamine 1 receptor agonist which is used intravenously for the treatment of hypertension in adults, can also be effective in producing deliberate hypotension in children scheduled to undergo a surgery. The study, according to the lead author, Dr. Gregory Hammer, affects pediatric labeling for fenoldopam and guides practitioners about appropriate intraoperative dosing for deliberate hypotension.